NeuroBo Pharmaceuticals Files 8-K Report
Ticker: MTVA · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
NeuroBo Pharma filed an 8-K, mostly boilerplate with exhibits. No major news.
AI Summary
On April 17, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided text. The company, formerly known as Gemphire Therapeutics Inc., is incorporated in Delaware and based in Cambridge, MA.
Why It Matters
This 8-K filing indicates NeuroBo Pharmaceuticals is fulfilling its reporting obligations with the SEC, which is standard procedure for publicly traded companies. The filing itself does not disclose new material information based on the provided text.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information that suggests an immediate change in risk for the company.
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- Gemphire Therapeutics Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Principal executive offices
- April 17, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for NeuroBo Pharmaceuticals?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
When was this 8-K report filed by NeuroBo Pharmaceuticals?
This 8-K report was filed on April 17, 2024.
What was NeuroBo Pharmaceuticals' former company name?
NeuroBo Pharmaceuticals, Inc.'s former company name was Gemphire Therapeutics Inc., with a date of name change on March 31, 2015.
In which state is NeuroBo Pharmaceuticals incorporated?
NeuroBo Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of NeuroBo Pharmaceuticals?
The business address of NeuroBo Pharmaceuticals is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-04-17 08:30:33
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240417x8k.htm (8-K) — 42KB
- nrbo-20240417xex99d1.htm (EX-99.1) — 17KB
- nrbo-20240417x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240417xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-005222.txt ( ) — 230KB
- nrbo-20240417.xsd (EX-101.SCH) — 3KB
- nrbo-20240417_lab.xml (EX-101.LAB) — 15KB
- nrbo-20240417_pre.xml (EX-101.PRE) — 9KB
- nrbo-20240417x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On April 17, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company" ) issued a press release announcing the dosing of the first patient in the single ascending dose (SAD) Part 1 of its two-part Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated April 17, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: April 17, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer